Raras
Buscar doenças, sintomas, genes...
Ataxia cerebelosa metabólica autossômica recessiva
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A ataxia de Friedreich (AF) é um distúrbio neurodegenerativo raro, hereditário, autossômico recessivo que afeta principalmente o sistema nervoso, causando danos progressivos à medula espinhal, aos nervos periféricos e ao cerebelo, levando à coordenação muscular comprometida (ataxia). A condição geralmente se manifesta na infância ou adolescência, com sintomas iniciais que incluem dificuldade para caminhar, perda de equilíbrio e má coordenação. À medida que a doença progride, ela também pode afetar a fala, a visão e a audição. Muitos indivíduos com ataxia de Friedreich desenvolvem escoliose, diabetes e cardiomiopatia hipertrófica, uma condição cardíaca grave que é uma das principais causas de mortalidade em pacientes.

Pesquisas ativas
1 ensaio
1 total registrados no ClinicalTrials.gov
Medicamentos
2 registrados
CHENODIOL, LOVASTATIN

Tem tratamento?

2 medicamentos registrados
Ver detalhes, fases e interações →
CHENODIOLLOVASTATIN
🏥
SUS: Cobertura mínimaScore: 20%
Centros em: PA, PR, SC, RS, ES +8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
57 sintomas
👁️
Olhos
25 sintomas
💪
Músculos
11 sintomas
🦴
Ossos e articulações
11 sintomas
🫃
Digestivo
10 sintomas
❤️
Coração
9 sintomas

+ 114 sintomas em outras categorias

Características mais comuns

Ataxia da marcha progressiva
Catarata
Nível urinário elevado de álcool biliar
Anormalidade da condução motora central
Tempo de protrombina prolongado
Deficiência visual
264sintomas
Sem dados (264)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 264 características clínicas mais associadas, ordenadas por frequência.

Ataxia da marcha progressivaProgressive gait ataxia
CatarataCataract
Nível urinário elevado de álcool biliarElevated urinary bile alcohol level
Anormalidade da condução motora centralAbnormality of central motor conduction
Tempo de protrombina prolongadoProlonged prothrombin time

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Últimos 10 anos200publicações
Pico201832 papers
Linha do tempo
2026Hoje · 2026🧪 2009Primeiro ensaio clínico📈 2018Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

8 genes identificados com associação a esta condição.

Autosomal recessive
POLGDNA polymerase subunit gamma-1Candidate gene tested inTolerante
FUNÇÃO

Catalytic subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Replicates both heavy and light strands of the circular mtDNA genome using a single-stranded DNA template, RNA primers and the four deoxyribonucleoside triphosphates as substrates (PubMed:11477093, PubMed:11897778, PubMed:15917273, PubMed:19837034, PubMed:9558343). Has 5' -> 3' polymerase activity. Functionally interacts with TWNK and SSBP1 at the replication fork to form a highly processiv

LOCALIZAÇÃO

MitochondrionMitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (1)
Strand-asynchronous mitochondrial DNA replication
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
48.3 TPM
Linfócitos
42.0 TPM
Baço
41.5 TPM
Útero
40.9 TPM
Pulmão
38.7 TPM
OUTRAS DOENÇAS (11)
sensory ataxic neuropathy, dysarthria, and ophthalmoparesismitochondrial DNA depletion syndrome 4bmitochondrial DNA depletion syndrome 4amitochondrial disease
HGNC:9179UniProt:P54098
GRID2Glutamate receptor ionotropic, delta-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Member of the ionotropic glutamate receptor family, which plays a crucial role in synaptic organization and signal transduction in the central nervous system. Although it shares structural features with ionotropic glutamate receptors, does not bind glutamate as a primary ligand (PubMed:34936451). Promotes synaptogenesis and mediates the D-Serine-dependent long term depression signals and AMPA receptor endocytosis of cerebellar parallel fiber-Purkinje cell (PF-PC) synapses through the NRX1B-CBLN1

LOCALIZAÇÃO

Postsynaptic cell membrane

MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 18

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR18 features include progressive cerebellar atrophy, delayed psychomotor development, severely impaired gait, ocular movement abnormalities, and intellectual disability.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
10.4 TPM
Cérebro - Hemisfério cerebelar
7.5 TPM
Testículo
6.2 TPM
Brain Nucleus accumbens basal ganglia
1.8 TPM
Hipotálamo
1.6 TPM
OUTRAS DOENÇAS (1)
autosomal recessive spinocerebellar ataxia 18
HGNC:4576UniProt:O43424
GRM1Metabotropic glutamate receptor 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol-calcium second messenger system. May participate in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum (PubMed:24603153, PubMed:28886343, PubMed:7476890).

LOCALIZAÇÃO

Cell membranePostsynaptic cell membraneCell projection, dendrite

VIAS BIOLÓGICAS (3)
G alpha (q) signalling eventsClass C/3 (Metabotropic glutamate/pheromone receptors)Neurexins and neuroligins
MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 13

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR13 is characterized by delayed psychomotor development beginning in infancy. Affected individuals show mild to profound intellectual disability with poor or absent speech as well as gait and stance ataxia and hyperreflexia.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
38.4 TPM
Cerebelo
30.6 TPM
Brain Frontal Cortex BA9
5.7 TPM
Córtex cerebral
3.6 TPM
Brain Anterior cingulate cortex BA24
3.6 TPM
OUTRAS DOENÇAS (3)
spinocerebellar ataxia 44autosomal recessive spinocerebellar ataxia 13chondromyxoid fibroma
HGNC:4593UniProt:Q13255
MTTPMicrosomal triglyceride transfer protein large subunitDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces (PubMed:15897609, PubMed:16478722, PubMed:22236406, PubMed:23475612, PubMed:25108285, PubMed:26224785, PubMed:8876250, PubMed:8939939). Required for the assembly and secretion of plasma lipoproteins that contain apolipoprotein B (PubMed:16478722, PubMed:23475612, PubMed:26224785, PubMed:8876250, PubMed:8939939). May be involved in regulating cholesteryl ester biosynthesis in cells that prod

LOCALIZAÇÃO

Endoplasmic reticulumGolgi apparatus

VIAS BIOLÓGICAS (3)
VLDL assemblyChylomicron assemblyLDL remodeling
MECANISMO DE DOENÇA

Abetalipoproteinemia

An autosomal recessive disorder of lipoprotein metabolism. Affected individuals produce virtually no circulating apolipoprotein B-containing lipoproteins (chylomicrons, VLDL, LDL, lipoprotein(A)). Malabsorption of the antioxidant vitamin E occurs, leading to spinocerebellar and retinal degeneration.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
31.1 TPM
Intestino delgado
24.7 TPM
Testículo
7.1 TPM
Ovário
1.8 TPM
Linfócitos
1.2 TPM
OUTRAS DOENÇAS (1)
abetalipoproteinemia
HGNC:7467UniProt:P55157
TTPAAlpha-tocopherol transfer proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Binds alpha-tocopherol, enhances its transfer between separate membranes, and stimulates its release from liver cells (PubMed:7887897). Binds both phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 4,5-bisphosphate; the resulting conformation change is important for the release of the bound alpha-tocopherol (By similarity)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Vitamin E transport
MECANISMO DE DOENÇA

Ataxia with vitamin E deficiency

An autosomal recessive disease characterized by undetectable or markedly reduced plasma levels of vitamin E, spinocerebellar degeneration, ataxia, areflexia and proprioception loss.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
34.2 TPM
Brain Caudate basal ganglia
2.8 TPM
Brain Nucleus accumbens basal ganglia
2.7 TPM
Cérebro - Amígdala
2.1 TPM
Brain Anterior cingulate cortex BA24
2.1 TPM
OUTRAS DOENÇAS (1)
familial isolated deficiency of vitamin E
HGNC:12404UniProt:P49638
PEX10Peroxisome biogenesis factor 10Candidate gene tested inTolerante
FUNÇÃO

E3 ubiquitin-protein ligase component of a retrotranslocation channel required for peroxisome organization by mediating export of the PEX5 receptor from peroxisomes to the cytosol, thereby promoting PEX5 recycling (PubMed:24662292). The retrotranslocation channel is composed of PEX2, PEX10 and PEX12; each subunit contributing transmembrane segments that coassemble into an open channel that specifically allows the passage of PEX5 through the peroxisomal membrane (By similarity). PEX10 also regula

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (2)
Peroxisomal protein importE3 ubiquitin ligases ubiquitinate target proteins
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 7

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
33.5 TPM
Glândula adrenal
23.3 TPM
Brain Spinal cord cervical c-1
22.1 TPM
Nervo tibial
20.8 TPM
Fibroblastos
20.1 TPM
OUTRAS DOENÇAS (5)
peroxisome biogenesis disorder 6Bperoxisome biogenesis disorder 6A (Zellweger)autosomal recessive ataxia due to PEX10 deficiencyZellweger spectrum disorders
HGNC:8851UniProt:O60683
GBA2Non-lysosomal glucosylceramidaseCandidate gene tested inTolerante
FUNÇÃO

Non-lysosomal glucosylceramidase that catalyzes the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) to free glucose and ceramides (such as N-acylsphing-4-enine) (PubMed:17105727, PubMed:30308956, PubMed:32144204). GlcCers are membrane glycosphingolipids that have a wide intracellular distribution (By similarity). They are the main precursors of more complex glycosphingolipids that play a role in cellular growth, differentiation, adhesion, signaling

LOCALIZAÇÃO

Endoplasmic reticulum membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Spastic paraplegia 46, autosomal recessive

A neurodegenerative disorder characterized by onset in childhood of slowly progressive spastic paraplegia and cerebellar signs. Some patients have cognitive impairment, cataracts, and cerebral, cerebellar, and corpus callosum atrophy on brain imaging.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
137.0 TPM
Cérebro - Hemisfério cerebelar
119.2 TPM
Tireoide
100.6 TPM
Intestino delgado
98.6 TPM
Pituitária
87.5 TPM
OUTRAS DOENÇAS (2)
hereditary spastic paraplegia 46autosomal recessive cerebellar ataxia with late-onset spasticity
HGNC:18986UniProt:Q9HCG7
CYP27A1Sterol 26-hydroxylase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cytochrome P450 monooxygenase that catalyzes regio- and stereospecific hydroxylation of cholesterol and its derivatives. Hydroxylates (with R stereochemistry) the terminal methyl group of cholesterol side-chain in a three step reaction to yield at first a C26 alcohol, then a C26 aldehyde and finally a C26 acid (PubMed:12077124, PubMed:21411718, PubMed:28190002, PubMed:9660774). Regulates cholesterol homeostasis by catalyzing the conversion of excess cholesterol to bile acids via both the 'neutra

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Synthesis of bile acids and bile salts via 27-hydroxycholesterolEndogenous sterolsSynthesis of bile acids and bile salts via 24-hydroxycholesterolSynthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
MECANISMO DE DOENÇA

Cerebrotendinous xanthomatosis

Rare sterol storage disorder characterized clinically by progressive neurologic dysfunction, premature atherosclerosis, and cataracts.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
332.0 TPM
Nervo tibial
127.6 TPM
Pulmão
119.5 TPM
Brain Spinal cord cervical c-1
113.6 TPM
Aorta
85.9 TPM
OUTRAS DOENÇAS (1)
cerebrotendinous xanthomatosis
HGNC:2605UniProt:Q02318

Medicamentos e terapias

CHENODIOLPhase 4

Mecanismo: Bile acid receptor FXR agonist

LOVASTATINPhase 2

Mecanismo: HMG-CoA reductase inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

1,015 variantes patogênicas registradas no ClinVar.

🧬 POLG: NM_002693.3(POLG):c.2157+2T>C ()
🧬 POLG: NM_002693.3(POLG):c.1315C>T (p.Gln439Ter) ()
🧬 POLG: NM_002693.3(POLG):c.2669A>G (p.Asp890Gly) ()
🧬 POLG: NM_002693.3(POLG):c.2342C>A (p.Ala781Asp) ()
🧬 POLG: NM_002693.3(POLG):c.2421dup (p.Ile808fs) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
2Fase 21
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 2 medicamentos · 1 ensaio
✓ Aprovados — podem ser usados hoje
CHENODIOL
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Ataxia cerebelosa metabólica autossômica recessiva

Centros de Referência SUS

21 centros habilitados pelo SUS para Ataxia cerebelosa metabólica autossômica recessiva

Centros para Ataxia cerebelosa metabólica autossômica recessiva

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Generation of eight human induced pluripotent stem cells lines from patients with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).

Stem cell research2026 Mar

Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is a rare inherited neurodegenerative disorder causing progressive spasticity, ataxia and peripheral neuropathy, leading to significant motor and sensory impairments. To advance the study of ARSACS pathogenesis and therapeutic development, we generated eight induced pluripotent stem cell (iPSC) lines from patient-derived fibroblasts or peripheral blood mononuclear cells (PBMCs) using non-integrating Sendai virus-based reprogramming method and covering four different SACS gene mutations. These iPSC lines provide a powerful platform to investigate disease mechanisms, evaluate therapeutic candidates, and support the development of personalized medicine approaches for ARSACS.

#2

Mild and late onset forms of type I 3-methylglutaconic aciduria presenting as isolated cerebellar ataxia without leukodystrophy: case reports and phenotype expansion.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026 Jan 02

Type I 3-Methylglutaconic Aciduria (MGCA1) is a metabolic disorder inherited in an autosomal recessive manner. It is caused by a deficiency in the 3-methylglutaconyl-CoA hydratase encoded by the AUH gene, leading to abnormal excretion of urinary organic acids. While the pediatric phenotype encompasses a spectrum ranging from isolated developmental delay to severe forms with leukodystrophy, developmental delay, spastic tetraplegia and movement disorders, the adult phenotype corresponds to a leukodystrophy with spastic ataxia, progressive dementia, and optic neuropathy. Due to its rarity, MGCA1 is most likely underdiagnosed, or diagnosed with an important delay, leading to inadequate care or genetic counselling. A better understanding of the disease's phenotype is thus required to facilitate its clinical and genetic diagnosis, in turn favoring clinical care and genetic counselling. We report two new MGCA1 patients, including an adult male patient with pure, late-onset, and progressive cerebellar ataxia, without optic neuropathy or leukodystrophy. A young female patient case is also reported with moderate developmental delay and leukodystrophy, offering 14-year follow-up data under carnitine supplementation. In both cases, urinary organic acid chromatography was critical to the diagnostic process by demonstrating abnormal and specific urinary organic acids excretion. The description of new, mild and/or late-onset phenotypes expands the clinical and radiological spectrum of MGCA1. Our results show that late-onset MGCA1 patients may present with pure cerebellar ataxia without leukodystrophy, contrasting with current knowledge. These results support the fact that AUH should always be sequenced in patients with pure cerebellar ataxia, but also that urinary organic acid chromatography being a simple, rapid, and cost-effective test, should be performed as a first-tier analysis in all patients with unresolved neurological symptoms. The importance of identifying MGCA1 patients is reinforced by the possibility of implementing a low-risk and possibly effective therapy with low-protein diet and L-carnitine supplementation.

#3

From Neonatal Encephalopathy to Adult Survival: Revisiting the Natural History of D-Bifunctional Protein Deficiency in a Multicentre International Case Series.

Journal of inherited metabolic disease2026 Jan

D-bifunctional protein deficiency (DBP-D) is a rare autosomal recessive peroxisomal disorder caused by biallelic pathogenic HSD17B4 variants. Its clinical spectrum ranges from severe neonatal-onset encephalopathy to milder, juvenile-onset forms, but comprehensive data on long-term outcomes remain limited. We conducted a retrospective, multicentre review of 26 DBP-D patients managed at seven centres in the United Kingdom and Spain from 1982 to 2024. Clinical, biochemical, neuroimaging, neurophysiological, and genetic data were systematically collected. A literature review was performed to contextualize our findings. Most patients (92%) presented within the first 5 days of life with neonatal seizures and hypotonia. Mortality was high: 77% died before the age of 2 years and 20% between ages two and five. Notably, three patients survived beyond 5 years, including one with neonatal-onset now aged 19. Two others had infantile-juvenile presentations with hearing loss, ataxia, and cerebellar atrophy. While 68% of patients had elevated very long-chain fatty acids (VLCFAs), 32% had normal or mildly raised levels; all of these survived beyond 2 years. Pathogenic variants were distributed across all three HSD17B4 domains, with 14 novel alleles identified. Neuroimaging findings varied with severity: polymicrogyria and cysts predominated in neonatal-onset cases, while cerebellar atrophy was typical in later-onset survivors. This study expands the clinical and genetic landscape of DBP-D, demonstrating that survival into adulthood is possible and that normal or mildly elevated VLCFA levels are associated with milder phenotypes. Early molecular testing is essential in all suspected cases, even with normal VLCFAs, to guide diagnosis, prognosis, and long-term care.

#4

An Unstable ATG2A Variant Causes a Neurodegenerative Disorder via Impaired Autophagy and Proteotoxic Stress in Brain Atrophy.

Clinical genetics2026 Jan

Autophagy is a critical cellular process for maintaining proteostasis and neuronal health. Disruption of this pathway is increasingly recognized in pediatric neurodegenerative disorders. Here, we study a novel previously uncharacterized homozygous and autosomal recessive missense variant, c.1372G>C (p.Gly433Ala), in the autophagy gene ATG2A, identified in a 3-year-old female proband presenting with developmental regression, seizures, cerebellar ataxia, and MRI-confirmed diffuse cerebral and cerebellar atrophy. The affected residue, Gly433, is evolutionarily conserved across eukaryotes and predicted to be structurally and functionally critical. Computational modeling and molecular dynamics simulations revealed that the G433A substitution induces local β-sheet extension, increased protein flexibility, higher aggregation propensity, and global structural destabilization. Proband-derived fibroblasts expressing ATG2A-G433A showed normal transcript and protein levels, but exhibited mislocalization of ATG2A to the cytosol, reduced colocalization with LC3B, loss of autophagosome formation, and a marked increase in protein aggregates. Proteotoxic stress was further evidenced by significant accumulation of Proteostat- and SQSTM1-positive granules. Additionally, transcript levels of unfolded protein response markers (GRP78, PERK, ATF4, and CHOP) were significantly upregulated, suggesting increased ER stress signaling. Cell cycle analysis revealed a substantial increase in cell death in proband fibroblasts. Overall, our findings identify ATG2A as a potentially novel disease gene and its G433A variant as a pathogenic substitution that disrupts autophagy and proteostasis, driving neurodegeneration via aggregation-prone misfolding and autophagy failure. This work depicts the first clinical spectrum of ATG2A-related neurodegenerative disorders and highlights the importance of autophagy maintenance in pediatric neurodevelopmental processes.

#5

Variants in MTNAP1 underlie a neurodegenerative disorder by impairing mitochondrial stability.

NPJ genomic medicine2026 Feb 20

Mutations in genes encoding mitochondrial proteins are increasingly recognized as a major cause of neurodegenerative disorders, owing to the role of mitochondria in neuronal energy metabolism and signaling. Here, we investigate MTNAP1 (mitochondrial nucleoid-associated protein 1) as a novel gene associated with an autosomal recessive neurodevelopmental disorder characterized by progressive cerebral and cerebellar atrophy. Three affected probands from two unrelated families presented with global developmental delay, ataxia, spasticity, seizures, and progressive neurological decline, with MRI revealing generalized cerebral and cerebellar volume loss and thinning of the corpus callosum. Trio-based exome sequencing uncovered two ultra-rare, biallelic loss-of-function variants in MTNAP1: a homozygous missense variant (p.G553R) in two siblings and a homozygous nonsense variant (p.Y13X) in an unrelated proband. Functional studies in proband-derived fibroblasts and MTNAP1-silenced neuronal cells implicated profound mitochondrial fragmentation, reduced oxidative phosphorylation capacity, increased reactive oxygen species accumulation, and premature senescence-like stress responses. Structural modeling and biophysical analyses revealed that the p.G553R variant destabilizes the MTNAP1 fold, disrupts its DNA- and membrane-binding interfaces, and induces aberrant aggregation, leading to loss of mitochondrial integrity. Collectively, our findings suggest MTNAP1 as a crucial regulator of mitochondrial homeostasis and identify pathogenic MTNAP1 variants as the cause of a novel, progressive neurodegenerative disorder.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 199

2026

Variants in MTNAP1 underlie a neurodegenerative disorder by impairing mitochondrial stability.

NPJ genomic medicine
2026

Generation of eight human induced pluripotent stem cells lines from patients with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).

Stem cell research
2026

Mild and late onset forms of type I 3-methylglutaconic aciduria presenting as isolated cerebellar ataxia without leukodystrophy: case reports and phenotype expansion.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

From Neonatal Encephalopathy to Adult Survival: Revisiting the Natural History of D-Bifunctional Protein Deficiency in a Multicentre International Case Series.

Journal of inherited metabolic disease
2025

Systematic Phenotyping and Molecular Analysis of the Woozy Mouse: A Preclinical Model of Cerebellar Ataxia.

Molecular neurobiology
2025

Dual cancers in Ataxia-Telangiectasia: a case report and literature review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Sacsin deletion decreases cell viscoelasticity and motility in a glial cell model of autosomal recessive spastic ataxia of Charlevoix Saguenay.

Archives of biochemistry and biophysics
2025

Long-term benefits of TUDCA supplement in ARSACS zebrafish model.

Scientific reports
2026

An Unstable ATG2A Variant Causes a Neurodegenerative Disorder via Impaired Autophagy and Proteotoxic Stress in Brain Atrophy.

Clinical genetics
2025

S100B Mitigates Cytoskeletal and Mitochondrial Alterations in a Glial Cell Model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay.

Molecular neurobiology
2025

Riboflavin treatment in L-2-hydroxyglutaric aciduria: report on a pediatric patient and literature review.

Journal of applied genetics
2025

Alterations in the Na+/H+ Exchanger NHE6 and Glutamate Transporters may Influence Purkinje Cell Fate in ARSACS.

Cerebellum (London, England)
2025

Expanding the spectrum of ATP8A2 mutations: a new splicing variant and systematic review of CAMRQ4 syndrome.

Molecular biology reports
2025

Identification of a large homozygous RNF216 deletion in a Chinese patient with gordon holmes syndrome.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Autosomal Recessive Ataxias in Northeast Brazil: A Regional Multicenter Case Series.

Cerebellum (London, England)
2025

Functional Characterization of Parallel Fiber-Purkinje Cell Synapses in Two Friedreich's Ataxia Mouse Models.

Cerebellum (London, England)
2025

Neurochemical alterations in the cerebellum of Friedreich's Ataxia mouse models.

Experimental neurology
2025

Whole Blood DNA Methylation Analysis Reveals Epigenetic Changes Associated with ARSACS.

Cerebellum (London, England)
2025

Choroid plexus-targeted viral gene therapy for alpha-mannosidosis, a prototypical neurometabolic lysosomal storage disease.

Human molecular genetics
2025

Modeling sacsin depletion in Danio Rerio offers new insight on retinal defects in ARSACS.

Neurobiology of disease
2024

Altered Cellular Metabolism Is a Consequence of Loss of the Ataxia-Linked Protein Sacsin.

International journal of molecular sciences
2025

EEFSEC deficiency: A selenopathy with early-onset neurodegeneration.

American journal of human genetics
2025

Drug repurposing screen for the rare disease ataxia-telangiectasia.

SLAS discovery : advancing life sciences R &amp; D
2024

The ataxia-telangiectasia disease protein ATM controls vesicular protein secretion via CHGA and microtubule dynamics via CRMP5.

Neurobiology of disease
2024

PHARC syndrome: an overview.

Orphanet journal of rare diseases
2025

Compound heterozygous mutation of AFG3L2 causes autosomal recessive spinocerebellar ataxia through mitochondrial impairment and MICU1 mediated Ca2+ overload.

Science China. Life sciences
2024

The Latest Developments for the Treatment of Ataxia Telangiectasia: A Narrative Review.

Cerebellum (London, England)
2024

Sacsin levels in PBMCs: A diagnostic assay for SACS variants in peripheral blood cells - A PROSPAX study.

Movement disorders : official journal of the Movement Disorder Society
2024

De Novo GRID2 Variant as a Cause of Ataxia with Oculomotor Apraxia and Alpha-Fetoprotein Elevation.

Cerebellum (London, England)
2025

Obsessive-compulsive disorder as a first manifestation of Ataxia with Oculomotor Apraxia type 2 due to a novel mutation of SETX gene.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Biallelic PTPMT1 variants disrupt cardiolipin metabolism and lead to a neurodevelopmental syndrome.

Brain : a journal of neurology
2024

Immune profiling and functional analysis of NK and T cells in ataxia telangiectasia.

Frontiers in immunology
2024

A human microglial cell model of autosomal recessive spastic ataxia of Charlevoix-Saguenay.

Biochimica et biophysica acta. Molecular basis of disease
2024

Loss of Elp1 in cerebellar granule cell progenitors models ataxia phenotype of Familial Dysautonomia.

Neurobiology of disease
2025

An Updated Canvas of the RFC1-mediated CANVAS (Cerebellar Ataxia, Neuropathy and Vestibular Areflexia Syndrome).

Molecular neurobiology
2024

Reduced levels of MRE11 cause disease phenotypes distinct from ataxia telangiectasia-like disorder.

Human molecular genetics
2024

Driving Mitochondrial Fission Improves Cognitive, but not Motor Deficits in a Mouse Model of Ataxia of Charlevoix-Saguenay.

Cerebellum (London, England)
2024

Late-onset cerebellar ataxia and a new frameshift L2HGDH mutation in a Chinese adult with L-2-hydroxyglutaric aciduria: a case report.

Acta neurologica Belgica
2024

Efficacy and safety of N-acetyl-L-leucine in patients with ataxia telangiectasia: A randomized, double-blind, placebo-controlled, crossover clinical trial.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2024

L-2 hydroxyglutaric aciduria: report of a Mexican-Mayan patient with the mutation c.569C>T and response to vitamin supplements and levocarnitine.

Tremor and other hyperkinetic movements (New York, N.Y.)
2024

Long-term follow-up of an attenuated presentation of NAXE-related disease, a potentially actionable neurometabolic disease: a case report.

Frontiers in neurology
2024

Transcriptional profiling of peripheral blood mononuclear cells identifies inflammatory phenotypes in Ataxia Telangiectasia.

Orphanet journal of rare diseases
2024

Single-center experience of congenital disorders of glycosylation syndrome screening in Tunisia: A retrospective study over a 15-year period (2007-2021).

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
2024

Vestibular Hypofunction in ARSACS Syndrome: A Possible Pitfall in the Differential Diagnosis of Recessive Cerebellar and Afferent Ataxias.

Neurology. Clinical practice
2024

Mutations in DNAJC19 cause altered mitochondrial structure and increased mitochondrial respiration in human iPSC-derived cardiomyocytes.

Molecular metabolism
2024

Role of DDX1 in the oxidative response of ataxia telangiectasia patient-derived fibroblasts.

Redox biology
2023

A Rare Case of Spinocerebellar Ataxia Autosomal Recessive 21 Presented with Liver Disease.

Advanced biomedical research
2023

Generation of four gene-edited human induced pluripotent stem cell lines with mutations in the ATM gene to model Ataxia-Telangiectasia.

Stem cell research
2023

In Cerebellar Atrophy of 12-Month-Old ATM-Null Mice, Transcriptome Upregulations Concern Most Neurotransmission and Neuropeptide Pathways, While Downregulations Affect Prominently Itpr1, Usp2 and Non-Coding RNA.

Cells
2024

ARV1 Gene: A Novel Cause of Autosomal Recessive Cerebellar Ataxia with Elevated Alpha Fetoprotein.

Cerebellum (London, England)
2023

Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome.

Expert opinion on investigational drugs
2023

Clinical, biochemical, and molecular characterization of mucopolysaccharidosis type III in 34 Egyptian patients.

American journal of medical genetics. Part A
2023

Autosomal Recessive Spinocerebellar Ataxia Type 9 With a Response to Phosphate Repletion: A Case Report.

Neurology. Genetics
2023

Biallelic MED27 variants lead to variable ponto-cerebello-lental degeneration with movement disorders.

Brain : a journal of neurology
2023

Loss of function variants in L2HGDH gene causing L-2-hydroxyglutaric aciduria.

Acta neurologica Belgica
2023

Dexamethasone induces p21cip1/waf1 expression via FoxO3a independently of the Lamin A/C-HDAC2 interaction in Ataxia Telangiectasia.

FEBS open bio
2023

Cross-talk between DNA damage response and the central carbon metabolic network underlies selective vulnerability of Purkinje neurons in ataxia-telangiectasia.

Journal of neurochemistry
2023

A mitochondrial-targeted antioxidant (MitoQ) improves motor coordination and reduces Purkinje cell death in a mouse model of ARSACS.

Neurobiology of disease
2023

A novel mutation in RNF216 gene in a Turkish case with Gordon Holmes syndrome.

BMC medical genomics
2023

Restoring calcium homeostasis in Purkinje cells arrests neurodegeneration and neuroinflammation in the ARSACS mouse model.

JCI insight
2024

Disproportionate Expression of ATM in Cerebellar Cortex During Human Neurodevelopment.

Cerebellum (London, England)
2023

SARM1 deletion delays cerebellar but not spinal cord degeneration in an enhanced mouse model of SPG7 deficiency.

Brain : a journal of neurology
2023

Severe neurometabolic phenotype in npc1 -/- zebrafish with a C-terminal mutation.

Frontiers in molecular neuroscience
2023

A novel C19orf12 frameshift mutation in a MPAN pedigree impairs mitochondrial function and connectivity leading to neurodegeneration.

Parkinsonism &amp; related disorders
2022

The J Domain of Sacsin Disrupts Intermediate Filament Assembly.

International journal of molecular sciences
2022

A Case of Gillespie Syndrome With Atypical Presentation.

Cureus
2023

Coexistence of spinocerebellar ataxia autosomal recessive type 21 and Ehlers-Danlos syndrome spondylodysplastic type 3 in a patient.

Clinical dysmorphology
2022

Multi-omic profiling reveals the ataxia protein sacsin is required for integrin trafficking and synaptic organization.

Cell reports
2023

The clinical and molecular spectrum of ZFYVE26-associated hereditary spastic paraplegia: SPG15.

Brain : a journal of neurology
2022

Treatable Ataxias: How to Find the Needle in the Haystack?

Journal of movement disorders
2022

Bi-Allelic COQ4 Variants Cause Adult-Onset Ataxia-Spasticity Spectrum Disease.

Movement disorders : official journal of the Movement Disorder Society
2022

The ARSACS disease protein sacsin controls lysosomal positioning and reformation by regulating microtubule dynamics.

The Journal of biological chemistry
2022

Next-Generation Sequencing Identifies Novel PMPCA Variants in Patients with Late-Onset Dominant Optic Atrophy.

Genes
2024

Primary CoQ10 deficiency with a severe phenotype due to the c.901 C > T (p.R301W) mutation in the COQ8A gene.

The International journal of neuroscience
2023

ANO10 Function in Health and Disease.

Cerebellum (London, England)
2022

In vitro study of polydopamine nanoparticles as protective antioxidant agents in fibroblasts derived from ARSACS patients.

Biomaterials science
2022

Novel homozygous pathogenic mitochondrial DNAJC19 variant in a patient with dilated cardiomyopathy and global developmental delay.

Molecular genetics &amp; genomic medicine
2023

Treatment and Management of Autosomal Recessive Cerebellar Ataxias: Current Advances and Future Perspectives.

CNS &amp; neurological disorders drug targets
2022

Case Report: Infantile Cerebellar-Retinal Degeneration With Compound Heterozygous Variants in ACO2 Gene-Long-Term Follow-Up of a Sibling.

Frontiers in genetics
2022

The natural history of ataxia-telangiectasia (A-T): A systematic review.

PloS one
2022

Epilepsia Partialis Continua a Clinical Feature of a Missense Variant in the ADCK3 Gene and Poor Response to Therapy.

Journal of molecular neuroscience : MN
2022

Widening the spectrum of spinocerebellar ataxia autosomal recessive type 10 (SCAR10).

BMJ case reports
2022

Persistent DNA damage associated with ATM kinase deficiency promotes microglial dysfunction.

Nucleic acids research
2022

Sacsin Deletion Induces Aggregation of Glial Intermediate Filaments.

Cells
2022

Integrated genome and transcriptome analyses reveal the mechanism of genome instability in ataxia with oculomotor apraxia 2.

Proceedings of the National Academy of Sciences of the United States of America
2022

How to Detect Isolated PEX10-Related Cerebellar Ataxia?

Neuropediatrics
2022

Genetics of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and Role of Sacsin in Neurodegeneration.

International journal of molecular sciences
2022

Dysfunction of cerebellar microglia in Ataxia-telangiectasia.

Glia
2022

Pontocerebellar atrophy is the hallmark neuroradiological finding in late-onset Tay-Sachs disease.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2021

Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS.

International journal of molecular sciences
2021

Assessment of Sacsin Turnover in Patients With ARSACS: Implications for Molecular Diagnosis and Pathogenesis.

Neurology
2022

Phenotype and pathology of the dilated cardiomyopathy with ataxia syndrome in children.

Journal of inherited metabolic disease
2021

Niemann-Pick disease type C in Palestine: genotype and phenotype of sixteen patients and report of a novel mutation in the NPC1 gene.

BMC medical genomics
2022

Autosomal recessive adult onset ataxia.

Journal of neurology
2021

Efficient Neuroprotective Rescue of Sacsin-Related Disease Phenotypes in Zebrafish.

International journal of molecular sciences
2021

Mechanisms Underlying the Suppression of Chromosome Rearrangements by Ataxia-Telangiectasia Mutated.

Genes
2021

Refractory T-cell/histiocyte-rich large B-cell lymphoma in a patient with ataxia-telangiectasia caused by novel compound heterozygous variants in ATM.

International journal of hematology
2021

Identification of a novel truncating variant in AHI1 gene and a brief review on mutations spectrum.

Molecular biology reports
2021

Gordon Holmes syndrome caused by two novel mutations in the PNPLA6 gene.

Clinical neurology and neurosurgery
2021

Genetic Dominant Variants in STUB1, Segregating in Families with SCA48, Display In Vitro Functional Impairments Indistinctive from Recessive Variants Associated with SCAR16.

International journal of molecular sciences
2021

Biallelic loss-of-function variations in PRDX3 cause cerebellar ataxia.

Brain : a journal of neurology
2021

Free sialic acid storage disorder: Progress and promise.

Neuroscience letters
2021

Brain hypometabolic changes in 14 adolescent-adult patients with Niemann-Pick disease type C assessed by 18F-fluorodeoxyglucose positron emission tomography.

Journal of neurology
2021

Expanding the β-III Spectrin-Associated Phenotypes toward Non-Progressive Congenital Ataxias with Neurodegeneration.

International journal of molecular sciences
2021

Elevated inflammatory responses and targeted therapeutic intervention in a preclinical mouse model of ataxia-telangiectasia lung disease.

Scientific reports
2021

Association of the Recurrent Rare Variant c.415T>C p.Phe139Leu in CLN5 With a Recessively Inherited Macular Dystrophy.

JAMA ophthalmology
2021

Alteration of Neural Stem Cell Functions in Ataxia and Male Sterility Mice: A Possible Role of β-Tubulin Glutamylation in Neurodegeneration.

Cells
2021

Progressive Myoclonic Epilepsy'-like presentation of Cerebrotendinous Xanthomatosis in an Indian Family with A Novel C.646+1G>A Splice Site Mutation.

Epilepsy &amp; behavior reports
2021

Expanding the clinical spectrum of STIP1 homology and U-box containing protein 1-associated ataxia.

Journal of neurology
2020

Snx14 proximity labeling reveals a role in saturated fatty acid metabolism and ER homeostasis defective in SCAR20 disease.

Proceedings of the National Academy of Sciences of the United States of America
2020

Chinese patient with cerebrotendinous xanthomatosis confirmed by genetic testing: A case report and literature review.

World journal of clinical cases
2021

Novel ACOX1 mutations in two siblings with peroxisomal acyl-CoA oxidase deficiency.

Brain &amp; development
2021

Mutations in Spliceosomal Genes PPIL1 and PRP17 Cause Neurodegenerative Pontocerebellar Hypoplasia with Microcephaly.

Neuron
2021

Clinical spectrum in multiple families with primary COQ10 deficiency.

American journal of medical genetics. Part A
2020

In vitro dexamethasone treatment does not induce alternative ATM transcripts in cells from Ataxia-Telangiectasia patients.

Scientific reports
2021

Role of Genetic Mutations of the Na+/H+ Exchanger Isoform 1, in Human Disease and Protein Targeting and Activity.

Molecular and cellular biochemistry
2020

Bone Marrow Transplantation as Therapy for Ataxia-Telangiectasia: A Systematic Review.

Cancers
2020

CHIP mutations affect the heat shock response differently in human fibroblasts and iPSC-derived neurons.

Disease models &amp; mechanisms
2021

Diabetes mellitus in an adolescent girl with intellectual disability caused by novel single base pair duplication in the PTRH2 gene: Expanding the clinical spectrum of IMNEPD.

Brain &amp; development
2020

Clinical Features and Molecular Genetics of Autosomal Recessive Ataxia in the Turkish Population.

Journal of pediatric neurosciences
2020

ATM Protein Kinase: Old and New Implications in Neuronal Pathways and Brain Circuitry.

Cells
2021

Familial writer's cramp: a clinical clue for inherited coenzyme Q10 deficiency.

Neurogenetics
2020

Novel homozygous variant of carbonic anhydrase 8 gene expanding the phenotype of cerebellar ataxia, mental retardation, and disequilibrium syndrome subtype 3.

American journal of medical genetics. Part A
2020

Diverse species-specific phenotypic consequences of loss of function sorting nexin 14 mutations.

Scientific reports
2020

Ataxia-telangiectasia: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management.

Expert review of clinical immunology
2020

Total Intravenous Anesthesia in Joubert Syndrome Patient for Otorhinolaryngology Surgery: A Case Report and Mini Review of the Literature.

The American journal of case reports
2021

ATM loss disrupts the autophagy-lysosomal pathway.

Autophagy
2020

Diagnosis and Management of Type 1 Sialidosis: Clinical Insights from Long-Term Care of Four Unrelated Patients.

Brain sciences
2020

Severe reaction to radiotherapy provoked by hypomorphic germline mutations in ATM (ataxia-telangiectasia mutated gene).

Molecular genetics &amp; genomic medicine
2020

Novel imaging and clinical phenotypes of CONDSIAS disorder caused by a homozygous frameshift variant of ADPRHL2: a case report.

BMC neurology
2020

Primary coenzyme Q10 deficiency due to COQ8A gene mutations.

Molecular genetics &amp; genomic medicine
2020

Interpretation challenges of novel dual-class missense and splice-impacting variant in POLR3A-related late-onset hereditary spastic ataxia.

Molecular genetics &amp; genomic medicine
2020

Significance of NT-proBNP and High-sensitivity Troponin in Friedreich Ataxia.

Journal of clinical medicine
2020

Clinical and genetic characteristics of type I sialidosis patients in mainland China.

Annals of clinical and translational neurology
2020

Clinical and Genetic Characterization of Autosomal Recessive Spinocerebellar Ataxia Type 16 (SCAR16) in Taiwan.

Cerebellum (London, England)
2020

Reversible Mitochondrial Fragmentation in iPSC-Derived Cardiomyocytes From Children With DCMA, a Mitochondrial Cardiomyopathy.

The Canadian journal of cardiology
2020

Wwox deficiency leads to neurodevelopmental and degenerative neuropathies and glycogen synthase kinase 3β-mediated epileptic seizure activity in mice.

Acta neuropathologica communications
2020

Novel compound heterozygous TMEM67 variants in a Vietnamese family with Joubert syndrome: a case report.

BMC medical genetics
2020

Characterisation of canine KCNIP4: A novel gene for cerebellar ataxia identified by whole-genome sequencing two affected Norwegian Buhund dogs.

PLoS genetics
2020

Choline transporter-like 1 deficiency causes a new type of childhood-onset neurodegeneration.

Brain : a journal of neurology
2019

A Preventable Ataxia: Cerebrotendinous Xanthomatosis.

Annals of Indian Academy of Neurology
2020

Neurological manifestations in adults with phenylketonuria: new cases and review of the literature.

Journal of neurology
2019

Bi-allelic variants in RNF170 are associated with hereditary spastic paraplegia.

Nature communications
2019

Changes in protein function underlie the disease spectrum in patients with CHIP mutations.

The Journal of biological chemistry
2020

Genetic and phenotypic features of patients with childhood ataxias diagnosed by next-generation sequencing gene panel.

Brain &amp; development
2019

Functional Transcriptome Analysis in ARSACS KO Cell Model Reveals a Role of Sacsin in Autophagy.

Scientific reports
2019

Novel POLR1C mutation in RNA polymerase III-related leukodystrophy with severe myoclonus and dystonia.

Molecular genetics &amp; genomic medicine
2019

Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin system.

Nature communications
2019

Refining the phenotype of the THG1L (p.Val55Ala mutation)-related mitochondrial autosomal recessive congenital cerebellar ataxia.

American journal of medical genetics. Part A
2019

Diminished OPA1 expression and impaired mitochondrial morphology and homeostasis in Aprataxin-deficient cells.

Nucleic acids research
2019

Primary Coenzyme Q deficiency Due to Novel ADCK3 Variants, Studies in Fibroblasts and Review of Literature.

Neurochemical research
2019

The Role of Iron in Friedreich's Ataxia: Insights From Studies in Human Tissues and Cellular and Animal Models.

Frontiers in neuroscience
2019

Autosomal Recessive Cerebellar Ataxias: Paving the Way toward Targeted Molecular Therapies.

Neuron
2019

Loss of the neurodevelopmental Joubert syndrome causing protein, Ahi1, causes motor and muscle development delays independent of central nervous system involvement.

Developmental biology
2019

Ataxia-telangiectasia: A review of clinical features and molecular pathology.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2019

Species-specific differences in nonlysosomal glucosylceramidase GBA2 function underlie locomotor dysfunction arising from loss-of-function mutations.

The Journal of biological chemistry
2019

Phenotypic spectrum of autosomal recessive retinitis pigmentosa without posterior column ataxia caused by mutations in the FLVCR1 gene.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2019

ATM is activated by ATP depletion and modulates mitochondrial function through NRF1.

The Journal of cell biology
2018

ADCK3-related Coenzyme Q10 Deficiency: A Potentially Treatable Genetic Disease.

Movement disorders clinical practice
2019

Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich's ataxia.

Movement disorders : official journal of the Movement Disorder Society
2019

GRP75 overexpression rescues frataxin deficiency and mitochondrial phenotypes in Friedreich ataxia cellular models.

Human molecular genetics
2018

Inflammation and transcriptional responses of peripheral blood mononuclear cells in classic ataxia telangiectasia.

PloS one
2018

Modulation of chromatin conformation by the histone deacetylase inhibitor trichostatin A promotes the removal of radiation-induced lesions in ataxia telangiectasia cell lines.

Mutation research. Genetic toxicology and environmental mutagenesis
2018

Ataxia telangiectasia alters the ApoB and reelin pathway.

Neurogenetics
2019

Sacsin, mutated in the ataxia ARSACS, regulates intermediate filament assembly and dynamics.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2018

Biochemical Characterization of the GBA2 c.1780G>C Missense Mutation in Lymphoblastoid Cells from Patients with Spastic Ataxia.

International journal of molecular sciences
2018

Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect.

Orphanet journal of rare diseases
2019

Variant in SCYL1 gene causes aberrant splicing in a family with cerebellar ataxia, recurrent episodes of liver failure, and growth retardation.

European journal of human genetics : EJHG
2018

Disrupted structure and aberrant function of CHIP mediates the loss of motor and cognitive function in preclinical models of SCAR16.

PLoS genetics
2018

Generation of a human iPSC line from a patient with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) caused by mutation in SACSIN gene.

Stem cell research
2018

Modeling Niemann-Pick disease type C1 in zebrafish: a robust platform for in vivo screening of candidate therapeutic compounds.

Disease models &amp; mechanisms
2018

GDAP2 mutations implicate susceptibility to cellular stress in a new form of cerebellar ataxia.

Brain : a journal of neurology
2018

Progressive ataxia of Charolais cattle highlights a role of KIF1C in sustainable myelination.

PLoS genetics
2018

STUB1 polyadenylation signal variant AACAAA does not affect polyadenylation but decreases STUB1 translation causing SCAR16.

Human mutation
2018

Mitochondrial redox sensing by the kinase ATM maintains cellular antioxidant capacity.

Science signaling
2018

Rare case of Gordon Holmes syndrome.

BMJ case reports
2018

Structures of ubiquitin-like (Ubl) and Hsp90-like domains of sacsin provide insight into pathological mutations.

The Journal of biological chemistry
2018

Extending the ophthalmological phenotype of Galloway-Mowat syndrome with distinct retinal dysfunction: a report and review of ocular findings.

BMC ophthalmology
2018

Nonsyndromic cerebellar ataxias associated with disorders of DNA single-strand break repair.

Handbook of clinical neurology
2018

De novo mutation screening in childhood-onset cerebellar atrophy identifies gain-of-function mutations in the CACNA1G calcium channel gene.

Brain : a journal of neurology
2018

PERK inhibition delays neurodegeneration and improves motor function in a mouse model of Marinesco-Sjögren syndrome.

Human molecular genetics
2018

Current and Promising Therapies in Autosomal Recessive Ataxias.

CNS &amp; neurological disorders drug targets
2018

A novel splice site variant in ITPR1 gene underlying recessive Gillespie syndrome.

American journal of medical genetics. Part A
2018

SNX14 mutations affect endoplasmic reticulum-associated neutral lipid metabolism in autosomal recessive spinocerebellar ataxia 20.

Human molecular genetics
2018

Inflammation, a significant player of Ataxia-Telangiectasia pathogenesis?

Inflammation research : official journal of the European Histamine Research Society ... [et al.]
2018

ACO2 homozygous missense mutation associated with complicated hereditary spastic paraplegia.

Neurology. Genetics
2018

Targeting the enhanced ER stress response in Marinesco-Sjögren syndrome.

Journal of the neurological sciences
2018

Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1.

JAMA neurology
2018

Most mutations that cause spinocerebellar ataxia autosomal recessive type 16 (SCAR16) destabilize the protein quality-control E3 ligase CHIP.

The Journal of biological chemistry
2018

Telangiectasias in Ataxia Telangiectasia: Clinical significance, role of ATM deficiency and potential pathophysiological mechanisms.

European journal of medical genetics
2017

Early VGLUT1-specific parallel fiber synaptic deficits and dysregulated cerebellar circuit in the KIKO mouse model of Friedreich ataxia.

Disease models &amp; mechanisms
2017

Homozygous GRID2 missense mutation predicts a shift in the D-serine binding domain of GluD2 in a case with generalized brain atrophy and unusual clinical features.

BMC medical genetics
2018

A Novel Homozygous Mutation in SPTBN2 Leads to Spinocerebellar Ataxia in a Consanguineous Family: Report of a New Infantile-Onset Case and Brief Review of the Literature.

Cerebellum (London, England)
2018

Congenital Disorders of Autophagy: What a Pediatric Neurologist Should Know.

Neuropediatrics
2018

Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism.

Metabolism: clinical and experimental
2017

Functional validation of novel MKS3/TMEM67 mutations in COACH syndrome.

Scientific reports
2017

Reversal of aberrant PI3K/Akt signaling by Salubrinal in a GalT-deficient mouse model.

Biochimica et biophysica acta. Molecular basis of disease
2017

Genetic ataxia telangiectasia porcine model phenocopies the multisystemic features of the human disease.

Biochimica et biophysica acta. Molecular basis of disease
2017

A SINE Insertion in ATP1B2 in Belgian Shepherd Dogs Affected by Spongy Degeneration with Cerebellar Ataxia (SDCA2).

G3 (Bethesda, Md.)

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Ataxia cerebelosa metabólica autossômica recessiva.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Ataxia cerebelosa metabólica autossômica recessiva

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Generation of eight human induced pluripotent stem cells lines from patients with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).
    Stem cell research· 2026· PMID 41529449mais citado
  2. Mild and late onset forms of type I 3-methylglutaconic aciduria presenting as isolated cerebellar ataxia without leukodystrophy: case reports and phenotype expansion.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology· 2026· PMID 41483232mais citado
  3. From Neonatal Encephalopathy to Adult Survival: Revisiting the Natural History of D-Bifunctional Protein Deficiency in a Multicentre International Case Series.
    Journal of inherited metabolic disease· 2026· PMID 41367148mais citado
  4. An Unstable ATG2A Variant Causes a Neurodegenerative Disorder via Impaired Autophagy and Proteotoxic Stress in Brain Atrophy.
    Clinical genetics· 2026· PMID 40631414mais citado
  5. Variants in MTNAP1 underlie a neurodegenerative disorder by impairing mitochondrial stability.
    NPJ genomic medicine· 2026· PMID 41720819mais citado
  6. Systematic Phenotyping and Molecular Analysis of the Woozy Mouse: A Preclinical Model of Cerebellar Ataxia.
    Mol Neurobiol· 2025· PMID 41350949recente
  7. Dual cancers in Ataxia-Telangiectasia: a case report and literature review.
    Neurol Sci· 2025· PMID 40848100recente
  8. Sacsin deletion decreases cell viscoelasticity and motility in a glial cell model of autosomal recessive spastic ataxia of Charlevoix Saguenay.
    Arch Biochem Biophys· 2025· PMID 40716484recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98096(Orphanet)
  2. MONDO:0020044(MONDO)
  3. GARD:19413(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55346092(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Ataxia cerebelosa metabólica autossômica recessiva
Compêndio · Raras BR

Ataxia cerebelosa metabólica autossômica recessiva

ORPHA:98096 · MONDO:0020044
Ensaios
1 ativos
Medicamentos
2 registrados
MedGen
UMLS
C5681517
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades